In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with significantly longer disease-free survival than placebo (24 months: 77% vs. 68%; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback